Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lorenzo Scatigno"'
Autor:
Antonio Corsello, Lorenzo Scatigno, Annalisa Govoni, Gianvincenzo Zuccotti, Frédéric Gottrand, Claudio Romano, Elvira Verduci
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Intestinal motility disorders represent a frequent problem in children with neurological impairment. These conditions are characterized by abnormal movements of the gut, which can result in symptoms such as constipation, diarrhea, reflux, and vomitin
Externí odkaz:
https://doaj.org/article/9432eb34e09d4410a157b2bb3b0940d3
Autor:
Anna Mandelli, Dario Dilillo, Ruggiero Francavilla, Antonio Corsello, Valeria Calcaterra, V. Fabiano, Annalisa Govoni, Gloria Pelizzo, Elena Zoia, Sara Vizzuso, Alessandra Bosetti, Gian Vincenzo Zuccotti, Flavia Indrio, Lorenzo Scatigno, Elvira Verduci, Martina Pascuzzi
The management of patients with spinal muscular atrophy type 1 (SMA1) is constantly evolving. In just a few decades the medical approach has switched from an exclusively palliative therapy to a targeted therapy, transforming the natural history of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae5d083a87b4b4a5278fe7505ba3511
Autor:
Giulia Fiore, Elvira Verduci, Lorenzo Scatigno, Elisabetta Di Profio, Antonio Corsello, Alessandra Bosetti, Gian Vincenzo Zuccotti
Publikováno v:
Nutrients, Vol 13, Iss 3412, p 3412 (2021)
Nutrients
Nutrients
Nutrition in early life is a crucial element to provide all essential substrates for growth. Although this statement may appear obvious, several studies have shown how the intake of micro and macronutrients in toddlers differs a lot from the recommen
Autor:
Ruggiero Francavilla, Antonio Corsello, Alessandra Bosetti, Dario Dilillo, Gloria Pelizzo, Lorenzo Scatigno, Flavia Indrio, V. Fabiano, Gian Vincenzo Zuccotti, Anna Mandelli, Sara Vizzuso, Annalisa Govoni, Elena Zoia, Valeria Calcaterra, Elvira Verduci, Martina Chiara Pascuzzi
Publikováno v:
Nutrients, Vol 13, Iss 2400, p 2400 (2021)
Nutrients
Nutrients
The management of patients with spinal muscular atrophy type 1 (SMA1) is constantly evolving. In just a few decades, the medical approach has switched from an exclusively palliative therapy to a targeted therapy, transforming the natural history of t